Latest research on Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Capecitabine indications

Several economic evaluations of regimens including oral preparations such as Capecitabine and tegafur-uracil have shown that such regimens are more cost effective than regimens comprising only injectable preparations [15, 30–32]. [source, 2016]
Consequently, Capecitabine makes MGMT more vulnerable to temozolomide cytotoxic effects. [source, 2016]
Because a 20% dose reduction of Capecitabine still evoked adverse effects (general weakness and electrolyte imbalance), chemotherapy with lapatinib alone was started. [source, 2016]
The results indicated that single Capecitabine maintenance for patients obtained CR, PR, or SD after short-term CapeOx provided an effective and tolerable therapeutic option. [source, 2016]
The CLASSIC trial that was conducted in South Korea, Taiwan, and China evaluated the effect of adjuvant chemotherapy with Capecitabine and Oxaliplatin for patients with stage II-IIIB GC who received curative gastrectomy with D2 LN dissection 29. [source, 2016]
The REAL-2 trial, a randomized phase III study, compared Oxaliplatin with Cisplatin and Capecitabine with 5-FU in 1003 patients with advanced esophagogastric cancer 37 and suggested that Oxaliplatin and Capecitabine were as effective as Cisplatin and 5-FU. [source, 2016]
However, Capecitabine, an oral fluoropyrimidine, can also be an effective alternative to 5-FU/LV as adjuvant treatment. [source, 2016]
A phase II trial is ongoing to determine whether combining hydroxychloroquine together with Capecitabine, Oxaliplatin, and bevacizumab is effective in treating patients with metastatic colorectal cancer [48]. [source, 2016]
It seems that PA-MSHA did not increase the anticancer effects of Capecitabine in MBC. [source, 2015]
The combination of 5-fluorouracil (5-FU) and folinic acid (Leucovorin), which enhances 5-FU effects by inhibiting thymilydate synthase, administered for six months, or oral fluoropyrimidines such as the 5-FU prodrugs Capecitabine [3] or tegafur [4], are able to reduce the risk of death by 30%, assuming an absolute increase of 10-13% in terms of survival. [source, 2015]